Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Classical hematology 1

Conditions

Anemia 30Neoplasms 16Lung Neoplasms 3Breast Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Small Cell Lung Carcinoma 1Pleural Effusion, Malignant 1Pleural Effusion 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Genital Neoplasms, Female 1Fatigue 1Carcinoma 1

Interventions

Cisplatin 4Carboplatin 2viscum album peptide 1sugemalimab 1rilotumumab 1ganitumab 1endostar protein 1Zoledronic Acid 1Valacyclovir 1Thiostrepton 1Surgical Procedures, Operative 1Paclitaxel 1N-(5-(2,3-dihydrobenzofuryl)sulfonyl)-N'-(3,4-dichlorophenyl)urea 1Etoposide 1Darbepoetin alfa 1Cetuximab 1Catheters, Indwelling 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Pleural Effusion, Malignant × Darbepoetin alfa × Clear all
NCT00858364 2022-11-30

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Amgen

Phase 3 Terminated
2,549 enrolled 19 charts
Classical hematologyThoracic

Anemia, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Pleural Effusion, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡